CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 64 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,000 | -75.0% | 649 | -79.7% | 0.00% | – |
| Q4 2020 | $8,000 | -98.6% | 3,204 | -96.4% | 0.00% | – |
| Q3 2020 | $575,000 | -7.3% | 88,317 | -7.7% | 0.00% | -100.0% |
| Q2 2020 | $620,000 | +79.2% | 95,663 | +5.9% | 0.00% | – |
| Q1 2020 | $346,000 | -30.5% | 90,352 | +7.2% | 0.00% | – |
| Q4 2019 | $498,000 | +564.0% | 84,276 | +783.7% | 0.00% | – |
| Q1 2019 | $75,000 | – | 9,537 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eversept Partners, LP | 522,042 | $1,117,170 | 0.13% |
| XTX MARKETS LLC | 26,041 | $56,000 | 0.12% |
| Samsara BioCapital, LLC | 300,000 | $642,000 | 0.06% |
| Ikarian Capital, LLC | 650,000 | $1,392,000 | 0.06% |
| Opaleye Management Inc. | 187,750 | $402,000 | 0.05% |
| SABBY MANAGEMENT, LLC | 108,026 | $231,000 | 0.04% |
| Anson Funds Management LP | 97,601 | $209,000 | 0.04% |
| Virtu Financial LLC | 83,221 | $178,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 47,084 | $101,000 | 0.02% |
| WEXFORD CAPITAL LP | 19,512 | $42,000 | 0.01% |